Do you need hormonals when micropathological indicators are normal?

Micro-degenerative kidney diseases are a common primary kidney-ball disease among children, and sometimes among adults. It is characterized by a mild disease in the basic structure of the kidney ball, which usually reacts well to hormone treatment. However, the need for hormonal use to continue when micropathological indicators return to normal is an issue requiring comprehensive consideration.I. Principles for the treatment of small cases of nephrosisThe treatment of micro-synthesis with kidney dysentery is mainly based on the use of sugary cortex hormones, such as the Pornison, in order to reduce immuno-mediated nephrocyte damage. Treatment is usually divided into two stages: induction and maintenance.II. Inducing mitigation phase of hormone treatmentDuring the induction and decomposition phase, patients are usually required to take higher doses of hormones to achieve rapid control of protein urine and oedema. Most patients will experience a marked improvement in weeks, with a decrease in protein urine and even a passivation.III. Maintenance phase of hormone treatmentOnce the protein urine is reduced or disappears, the patient will enter the maintenance phase. At this stage, hormonal doses will gradually decrease in order to prevent a recurrence of disease. The duration of maintenance is usually longer and may take months or even more.IV. Discontinuation of hormones after normal indicatorsRe-emergence risk: There is a high risk of re-emergence, especially after hormonal suspension. Therefore, even if the indicators were to return to normal, the immediate discontinuation of hormones was not recommended.Gradual reduction: Normally, doctors advise patients to gradually reduce hormonal doses after normal indicators, rather than to stop the drug. This reduces the probability of relapse and allows the body to adapt gradually to hormone reduction.Long-term maintenance: Some patients may need to maintain small doses of hormonal treatment for a long period of time to prevent a recurrence of disease.Individual differences: Discontinuation of hormones also depends on individual differences in the patient, including age, severity of the disease, responsiveness to hormones and the existence of complications.V. Timing and attention to the elimination of hormonesDoctor ‘ s guidance: The timing of the hormonal phase-out shall be determined by the doctor according to the patient ‘ s specific circumstances. As a rule, doctors develop a detoxification plan based on the patient ‘ s level of stability and treatment response.Monitoring indicators: In the process of reduction and detoxification, patients are required to regularly examine indicators such as urine protein, kidney function, and to monitor possible adverse effects of hormone treatment.Remittance treatment: If the patient has a relapse after reduction or withdrawal, hormonal treatment may need to be restarted and longer treatment may be required to control the condition.ConclusionsThe continued hormonal use of hormonals by persons with micro-diseases and kidneys after normal indicators is subject to medical assessment and guidance. In general, the patient needs to gradually reduce the amount under the supervision of a doctor and maintain the treatment for a period of time to reduce the risk of relapse. A sudden stoppage may lead to a recurrence of the disease, so the patient should follow medical instructions, review regularly and adjust the treatment programme to the doctor ‘ s recommendations. Through appropriate treatment and management, persons with micro-dimensions can effectively control their condition, reduce their relapse and protect their kidney function.